{"id":3079,"date":"2025-03-05T16:45:40","date_gmt":"2025-03-05T13:45:40","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=3079"},"modified":"2025-03-07T12:54:07","modified_gmt":"2025-03-07T09:54:07","slug":"pepgen-temporarily-pauses-exon-51-skipping-study","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/es\/pepgen-temporarily-pauses-exon-51-skipping-study\/","title":{"rendered":"PepGen pausa temporalmente el estudio de omisi\u00f3n del ex\u00f3n 51"},"content":{"rendered":"<p class=\"wp-block-paragraph\">PepGen, una empresa de biotecnolog\u00eda en etapa cl\u00ednica que avanza en la pr\u00f3xima generaci\u00f3n de terapias con oligonucle\u00f3tidos con el objetivo de transformar el tratamiento de enfermedades neuromusculares y neurol\u00f3gicas graves, anunci\u00f3 hoy su decisi\u00f3n voluntaria de pausar temporalmente el estudio de fase 2 CONNECT2-EDO51 de PGN-EDO51 en pacientes con distrofia muscular de Duchenne (DMD) hasta que la empresa pueda revisar los resultados de la cohorte de 10 mg\/kg en el estudio de fase 2 en curso CONNECT1-EDO51.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Las dos primeras cohortes del estudio CONNECT1 ya est\u00e1n completamente inscritas y se esperan datos de la cohorte de 10 mg\/kg durante el tercer trimestre de 2025. No se han observado nuevos problemas de seguridad relacionados con PGN-EDO51 desde la \u00faltima actualizaci\u00f3n de seguridad de la Compa\u00f1\u00eda al 23 de enero de 2025.<\/p>","protected":false},"excerpt":{"rendered":"<p>PepGen, a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced its voluntary decision to temporarily pause the Phase 2 CONNECT2-EDO51 study of PGN-EDO51 in patients with Duchenne muscular dystrophy (DMD) until the Company can review results from the [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3081,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[137,275,122,193,194,77,273,274],"class_list":["post-3079","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-clinical-trial","tag-connect1-edo51","tag-exon-51","tag-exon-51-skipping","tag-exon-51-treatment","tag-exon-skipping","tag-pepgen","tag-pgn-edo51"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/posts\/3079","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/comments?post=3079"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/posts\/3079\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/media\/3081"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/media?parent=3079"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/categories?post=3079"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/tags?post=3079"}],"curies":[{"name":"gracias","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}